Assay drift during shared facility campaign: risk assessment for patient safety
Identifying symptoms of assay drift is the first step in initiating an investigation. Common signals include:Click to read the full article.
Oncology Products
Assay drift during stability pull: containment CAPA and effectiveness checks
Detecting assay drift early is crucial to maintaining product quality and regulatory compliance. Symptoms indicative of assay drift during stability pulls may include:Click to read the full article.
Potency OOS during shared facility campaign: FDA/EMA investigation expectations
Symptoms related to potency OOS can manifest in various ways. Below are key signals that may indicate potential issues with product potency:Click to read the full article.
Cross-contamination risk during stability pull: risk assessment for patient safety
The first step in addressing cross-contamination risks is recognizing the symptoms or signals that may indicate a problem during stability pulls. Symptoms can manifest in various forms, including:Click to read…
Stability failure after equipment cleaning: risk assessment for patient safety
Before delving into the investigation process, it's vital to recognize the specific symptoms or signals that may indicate a stability failure. Common signals that should prompt immediate scrutiny include:Click to…
Occupational exposure limit breach in oncology manufacturing: FDA/EMA investigation expectations
Identifying the signs of a potential OEL breach is the first step in the investigative process. Symptoms may manifest as:Click to read the full article.
Cross-contamination risk during inspection prep: FDA/EMA investigation expectations
Identifying the symptoms or signals of potential cross-contamination is the first step in the investigation process. Employees and quality assurance professionals must remain vigilant for the following indicators:Click to read…
Occupational exposure limit breach in oncology manufacturing: risk assessment for patient safety
The initial step in responding to a potential OEL breach is to recognize the symptoms or signals that indicate an issue may exist. These signals can manifest in various forms:Click…
Potency OOS in oncology manufacturing: risk assessment for patient safety
Recognizing the symptoms or signals indicative of a potency OOS event is fundamental in initiating an effective investigation. Common signs that warrant immediate attention include:Click to read the full article.
Assay drift during shared facility campaign: FDA/EMA investigation expectations
Identifying symptoms of assay drift is the first step in effective investigation. Symptoms may manifest as deviations in test results, unexpected trends in data, or quality complaints from customers. Common…
Potency OOS during stability pull: FDA/EMA investigation expectations
Recognizing the symptoms of potential potency OOS deviations is the first step in your investigative process. Symptoms may manifest as:Click to read the full article.
Assay drift after equipment cleaning: FDA/EMA investigation expectations
The first step in addressing assay drift after equipment cleaning is to recognize the symptoms or signals that indicate an issue. Common manifestations include:Click to read the full article.